A COST VARIATION COMPARISON AMONG ORAL ANTI-MIGRAINE DRUGS AVAILABLE IN THE INDIAN MARKET

AKASH MISHRA; POOJA SOLANKI MISHRA; ANJALI KUSHWAH; KAMAYANI GUPTA

doi:10.22159/ijpps.2024v16i5.50777

Authors

AKASH MISHRA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0009-0008-5559-2935
POOJA SOLANKI MISHRA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0009-0004-9598-4993
ANJALI KUSHWAH Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0000-0001-6450-1750
KAMAYANI GUPTA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0000-0002-4745-0223

DOI:

https://doi.org/10.22159/ijpps.2024v16i5.50777

Keywords:

Anti-migraine drugs, Cost ratio, Cost percent variation, Migraine prophylaxis, Cost analysis

Abstract

Objective: Our study aimed to evaluate the cost per cent variation & cost ratio of different brands of oral anti-migraine drugs available in Indian market.

Methods: The cost of various commonly used oral anti-migraine drugs were taken from the latest issue of Current Index of Medical Specialities January 2022, Drug Today January-April 2022 and 1mg online site. Cost per cent variation and Cost ratio were calculated.

Results: A total of 7 single anti-migraine drugs and 9 Fixed-Dose Combinations (FDCs) showed a wide range of cost variation. The highest cost per cent variation of 433% was seen in Sumatriptan 50 mg with a cost ratio of 5.33 whereas Amitriptyline 10mg showed the lowest cost per cent variation of 47.9% with a cost ratio of 1.47. Among FDCs Naproxen 500mg + Sumatriptan 85mg showed the highest cost per cent variation of 400% with a cost ratio of 5.25 and Propranolol 40mg + Flunarizine 10mg showed the lowest cost per cent variation of 46.56% with a cost ratio of 1.46.

Conclusion: Our study showed a wide variation in the cost of oral anti-migraine drugs available in the Indian market which provides insight to the healthcare professional and gives Drug Price Control Order (DPCO) authorities to minimize the financial burden and improve patient compliance.

Downloads

Download data is not yet available.

References

Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Lifting the Burden: The Global Campaign against Headache. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID: 33267788; PMCID: PMC7708887.

Lars JS, Emma N, Timothy J S, Foad AA, Ahmed A, Rajaa M.Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):954-976. doi: 10.1016/S1474-4422(18)30322-3. PMID: 30353868; PMCID: PMC6191530.

Berg J. Economic evidence in migraine and other headaches: a review. Eur J Health Econ. 2004 Oct;5 Suppl1:S43-54. doi: 10.1007/s10198-005-0288-z. PMID: 15754073.

LanteriMM. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014 Jan;18(1):385. doi: 10.1007/s11916-013-0385-0. PMID: 24338699.

LantériMM, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011 May;31(7):837-50. doi: 10.1177/0333102411398400. Epub 2011 Apr 4. PMID: 21464078.

Valery LF, Emma N, Tahiya A, Marlena SB, Ettore B, Natacha B. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. PMID: 30879893; PMCID: PMC6459001.

Headache: Dennis L. Kasper. Harrison's Manual of Medicine, 19thed.McGraw-Hill Education;2016 [book] Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=1820&sectionid=127554784.

Das SC, Mandal M, Mandal SC. A Critical Study of Availability and Cost Variation between Different Brands: Impact on Access to Medicines. Indian J Pharm Sci. 2007,69(1):158-163. 9. Waldo DR. Outpatient prescription drug spending by the Medicare population. Health Care Financ Rev. 1987 Fall;9(1):83-9. PMID: 10312274; PMCID: PMC4192897.

Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of Pharmacoeconomics in current Indian healthcare system. J Res Pharm Pract. 2013 Jan;2(1):3-9. doi: 10.4103/2279-042X.114081. PMID: 24991597; PMCID: PMC4076893.

Current Index of Medical Specialties, UBM Medica India Pvt. Ltd.2022. January-April 2022.

Drug Today, Lorina Publications (India) Inc. 2022. January-April 2022.

Tiwari A, Reddy P. Cost analysis of Antifungal drugs available in India: A pharmacoeconomic perspective. Indian J PharmPharmacol. October-December 2016; 3(4); 192-196.

Gupta P, SankdiaRK, Marko S, Dubry L. A cost variation analysis of oral and topical antifungal agents available for the treatment of superficial fungal infections in India- an insight to the rising treatment cost. Asian J Pharm Clin Res.May2022;15; 7.doi:10.22159/ajpcr.2022v15i7.45467.

Rani V, Venepally S. A cost variation analysis study of drugs used in the management of benign prostatic hyperplasia available in the Indian market. Asian J Pharm Clin Res. March 2021;14;6. doi:10.22159/ajpcr.2021v14i6.41291.

Roy V, Gupta U, Gupta M, Agarwal AK. Prescribing practices in private health facilities in Delhi (India). Indian J Pharmacol. 2013 Sep-Oct;45(5):534-5. doi: 10.4103/0253-7613.117762. PMID: 24130397; PMCID: PMC3793533.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007 Sep;4(9): e283. doi: 10.1371/journal.pmed.0040283. PMID: 17896856; PMCID: PMC1989748.

King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002 Aug;43(4):462-9. PMID: 12187525.

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. PMID: 19050195; PMCID: PMC2713758.

Tilyard MW, Dovey SM, Rosenstreich D. General practitioners' views on generic medication and substitution. N Z Med J. 1990 Jul 11;103(893):318-20. PMID: 2371006.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23. PMID: 19776300.

Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. Health Aff (Millwood). 2009 Mar-Apr;28(2):546-56. doi: 10.1377/hlthaff.28.2.546. PMID: 19276015; PMCID: PMC2748784.

Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011 Apr;43(2):131-6. doi: 10.4103/0253-7613.77344. PMID: 21572645; PMCID: PMC3081449.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992 Dec;2(6):449-55. doi: 10.2165/00019053-199202060-00005. PMID: 10172052.

Roy V, Gupta U, Agarwal AK. Cost of medicines & their affordability in private pharmacies in Delhi (India). Indian J Med Res. 2012 Nov;136(5):827-35. PMID: 23287131; PMCID: PMC3573605.

Drug Cost Control Order, 2013, Government of India. Available at http://www.nppaindia.nic.in/DPCO2013. pdf. Accessed on 19 Dec. 2016. 21. Kotwani A. Will generic drug stores improve access to essential medicines for the poor in IndiaJ Public Health Policy 2010; 31:178-84.

Kotwani A. Commentary: will generic drug stores improve access to essential medicines for the poor in India J Public Health Policy. 2010 Jul;31(2):178-84. doi: 10.1057/jphp.2010.2. PMID: 20535100.